Walker Asset Management LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Walker Asset Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 17.0% in the 1st quarter, HoldingsChannel reports. The firm owned 9,979 shares of the biopharmaceutical company’s stock after buying an additional 1,452 shares during the quarter. Walker Asset Management LLC’s holdings in Pfizer were worth $277,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PFE. Advisor OS LLC increased its holdings in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after purchasing an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC grew its position in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 371 shares during the last quarter. King Wealth Management Group lifted its holdings in shares of Pfizer by 2.4% during the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares during the last quarter. Advance Capital Management Inc. increased its position in shares of Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 391 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC raised its stake in Pfizer by 1.4% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 28,952 shares of the biopharmaceutical company’s stock valued at $834,000 after purchasing an additional 396 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.08 on Friday, hitting $27.66. The stock had a trading volume of 9,217,688 shares, compared to its average volume of 40,969,020. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business’s fifty day moving average is $27.63 and its 200 day moving average is $27.73. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $38.99. The company has a market cap of $156.74 billion, a PE ratio of -463.42, a P/E/G ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.23 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were given a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.07%. Pfizer’s payout ratio is presently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Morgan Stanley increased their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $35.86.

Get Our Latest Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.